MAIA Biotechnology (MAIA) Suspends Common Stosk Sales

On November 15, 2023, MAIA Biotechnology (NYSE: MAIA) suspended sales of its common stock, par value $0.0001 per share (“Common Stock”), pursuant to that certain Sales Agreement, dated as of September 1, 2023 (the “Sales Agreement”), between the Company and ThinkEquity LLC (the “Agent”), the Company’s sales agent thereunder, and provided notice to the Agent that it is terminating the Sales Agreement, which termination will be effective 10 days after November 15, 2023, in accordance with the terms of the Sales Agreement. In accordance with the terms of the Sales Agreement, the Company was initially authorized to offer and sell shares of Common Stock having an aggregate offering price of up to up to $7,000,000 from time to time through the Agent, in an “at the market” equity offering program. Through November 15, 2023, the Company had sold an aggregate of 758,388 shares of Common Stock through the Agent under the Sales Agreement, resulting in gross proceeds of $1,667,084.40.

You May Also Be Interested In

• Absci prices $100M stock offering with Eli Lilly among investors
• Neuronetics promotes CTO to EVP, General Manager of Greenbrook
• Eldorado Gold elects nine directors at 2026 annual meeting